InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
12
T+90 hit rate
0%
T+90 mean return
-27.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Crockett Thomas Andrew, Chief Executive Officer. Director active across 1 company, notably KalVista Pharmaceuticals, Inc.. Cumulatively, 24 reports have been published. Split: 0 buy · 12 sells. Total volume traded: €2.4m. History available since 29 April 2021. The latest transaction was filed on 14 February 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations24 total
54,415 sharesCommon StockSEC:0001415889-24-004710:0
58,356 shares@ US$15.009334.0% of flowCommon StockSEC:0001415889-24-004120:0
122,500 sharesCommon StockSEC:0001415889-24-003475:0
9,300 shares@ US$16.17515.8% of flowCommon StockSEC:0001415889-24-002625:0
30,000 shares@ US$12.015113.6% of flowCommon StockSEC:0001209191-23-059907:0
33,583 sharesCommon StockSEC:0001209191-23-056267:0
8,000 shares0Common StockSEC:0001209191-23-054018:0
33,582 sharesCommon StockSEC:0001209191-23-046820:0
12,750 sharesCommon StockSEC:0001209191-23-031292:0
12,749 sharesCommon StockSEC:0001209191-23-012315:0
5,805 sharesCommon StockSEC:0001209191-22-058119:0
6,500 shares0Common StockSEC:0001209191-22-049030:0
5,805 sharesCommon StockSEC:0001209191-22-046855:0
10,000 shares@ US$17.06930.011% mcap13.9% of flowCommon StockSEC:0001209191-22-018184:0
10,000 shares@ US$17.18410.010% mcap13.2% of flowCommon StockSEC:0001209191-21-059042:0
10,000 shares@ US$17.18416.2% of flowCommon StockSEC:0001209191-21-059042
4,350 shares@ US$23.87870.0062% mcap7.8% of flowCommon StockSEC:0001209191-21-045093:0
4,350 shares@ US$23.87873.6% of flowCommon StockSEC:0001209191-21-045093
1,067 shares@ US$30.0381.1% of flowCommon StockSEC:0001209191-21-042450
1,067 shares@ US$30.0380.0019% mcap2.4% of flowCommon StockSEC:0001209191-21-042450:0
8,933 shares@ US$30.05490.015% mcap19.6% of flowCommon StockSEC:0001209191-21-040040:0
8,933 shares@ US$30.05499.2% of flowCommon StockSEC:0001209191-21-040040
4,750 shares0Common StockSEC:0001209191-21-036588:0
4,750 shares0Common StockSEC:0001209191-21-036588
24 of 24 declarations
About Crockett Thomas Andrew
Thomas Andrew Crockett is the CEO of KalVista Pharmaceuticals, Inc. He leads the company in developing treatments for rare diseases. Under his leadership, KalVista focuses on innovation and expanding its products in the market.
